News coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4723644877203 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
Shares of Zogenix (ZGNX) traded down $4.37 during trading on Monday, reaching $34.53. 2,456,531 shares of the company’s stock traded hands, compared to its average volume of 669,578. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.71 and a current ratio of 2.71. Zogenix has a 12-month low of $7.70 and a 12-month high of $42.60.
A number of research firms have issued reports on ZGNX. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $55.00 target price (up from $26.00) on shares of Zogenix in a research note on Friday, September 29th. Mizuho restated a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a research note on Wednesday, November 8th. JMP Securities started coverage on shares of Zogenix in a research note on Monday, November 27th. They issued an “outperform” rating and a $56.00 price objective for the company. Finally, BidaskClub cut shares of Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $42.67.
In other Zogenix news, major shareholder Life Sciences Maste Perceptive purchased 300,000 shares of the stock in a transaction on Tuesday, October 3rd. The shares were purchased at an average price of $37.50 per share, with a total value of $11,250,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-zogenix-zgnx-stock-price.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.